Paul Peter Tak’s oncolytic virus startup is jumping head-first into a new partnership, looking to tackle solid tumor CAR-Ts. Candel Therapeutics is joining forces with Carl June’s lab at the University of Pennsylvania to see if the herpes virus can boost the effectiveness of CAR-T therapies in solid tumors, the biotech announced Wednesday morning. No … Continue reading Using herpes virus vectors, Paul Peter Tak and Carl June team up to solve the CAR-T solid tumor challenge